In what stands as one of the most comprehensive vaccine safety studies across the globe, scientists have singled out unusual conditions that have surfaced after receiving COVID-19 vaccinations.
The study of 99 million vaccinated people in eight countries found a slight increase in heart inflammation cases following shots from Pfizer and Moderna, both mRNA vaccines.
Simultaneously, the AstraZeneca vaccine, which uses a different technology known as a viral vector, has been associated with a rare brain blood clot disorder.
The AstraZeneca vaccine has also been linked to a higher risk of Guillain-Barre syndrome, a neurological disorder that can sometimes lead to muscle weakness and, in rare instances, paralysis.
These findings are particularly significant against the backdrop of the 13.5 billion doses of COVID-19 vaccines administered globally to date an undertaking that has played a critical role in preserving lives during the pandemic.
The Global Vaccine Data Networks exhaustive research, detailed in the scholarly journal Vaccine, provides expansive insight into the matter. The networks publication, equipped with easy-to-navigate dashboards, transparently presents both its research methodology and the conclusions drawn for public examination.
The analysts involved in this study examined health data of 99 million individuals, primarily focused on 13 specific conditions considered to be of special interest for vaccine safety.
Evidence of myocarditis, which is inflammation of the heart muscle, was particularly recurrent among individuals after their first, second, or booster dose of an mRNA vaccine.
Modest spikes in incidence were noted especially following the administration of the second dose of the Moderna shot, which was also tied to a raised occurrence of pericarditis a swelling of the tissue surrounding the heart after initial and booster vaccinations.
A significant increase in the cases of Guillain-Barre syndrome was observed within 42 days of receiving the initial dose of AstraZenecas vaccine, also known as Vaxzevria.
The study documented an increase to 190 cases from the forecasted 66 based on natural incidence rates.
An uptick in cases of cerebral venous sinus thrombosis, an exceptionally rare type of cerebral clot, led to the restriction, or even discontinuation of the use of AstraZenecas vaccine in a number of countries, including Denmark.
Furthermore, a connection between this vaccine and myocarditis after the third dose was noted in specific demographics, albeit not as a widespread issue.
For more information, visit The Washington Times COVID-19 resource page.
Washington Times Staff can be reached at 202-636-3000.
VOTE: Do you plan on getting a Covid booster?
by The National Desk
FILE - A nurse administers a Moderna COVID-19 booster vaccine at an inoculation station next to Jackson State University in Jackson, Miss., Friday, Nov. 18, 2022. (AP Photo/Rogelio V. Solis)
Do you plan on getting a Covid booster? Vote in the poll above or click here.
In an era where the world grapples with the aftermath and ongoing challenges posed by the COVID-19 pandemic, the scientific community's relentless pursuit of answers brings to light findings of paramount importance. A recent extensive study, hailed as the largest of its kind, has meticulously mapped the terrain of vaccine safety, uncovering rare but significant side effects linked to various COVID-19 vaccines. Among these, heart-related inflammations such as myocarditis and pericarditis, along with blood clots including cerebral venous sinus thrombosis, stand out as concerns that warrant attention.
Delving deeper into the fabric of these findings, the study unveils an increased risk of Guillain-Barre syndrome and other neurological conditions like transverse myelitis and acute disseminated encephalomyelitis post-vaccination. These revelations come from a self-controlled case series focusing on the association between Pfizer/Moderna vaccination and thrombotic events among healthcare workers. It was discovered that there is a heightened risk of thrombosis following the initial two doses of vaccination, shedding light on the nuanced interplay between vaccine administration and the subsequent emergence of these rare side effects.
Furthermore, the study underscores the phenomenon of chronic post-vaccination syndrome, characterized by a constellation of symptoms that persist well beyond the immediate aftermath of vaccination. This highlights an urgent need for ongoing research to enhance vaccine safety protocols and mitigate the distress experienced by those affected.
At the heart of this study are the experiences of 1,575 healthcare workers, with a prominent representation from the age groups of 30-40 in women and 40-50 in men. Among them, a notable percentage had pre-existing conditions such as hypertension, diabetes, and asthma. The vaccines predominantly administered were Sputnik V and Oxford-AstraZeneca, with the majority of side effects manifesting within the first 24 hours post-vaccination. The most common adverse reactions were injection site pain and myalgia, yet post-vaccine COVID-19 infection was reported in a minority of 4.2% of cases, underscoring the vaccines' role in mitigating the risk of severe disease.
The study also delves into the critical aspect of thromboembolism risk, which appears to be modulated by prior vaccination status. Intriguingly, vaccinated individuals exhibited a lower risk, pointing to the vaccines' efficacy not only in lowering infection rates but also in reducing the likelihood of thromboembolic events.
In the unfolding narrative of COVID-19 and its vaccines, this comprehensive study serves as a crucial checkpoint. It not only brings to the forefront the rare side effects associated with vaccination but also emphasizes the vaccines' instrumental role in curbing the pandemic's spread and severity. The findings advocate for a balanced understanding, recognizing the imperative to safeguard public health while diligently working to refine vaccine safety.
In light of these revelations, the global community stands at a crossroads, equipped with knowledge that both cautions and guides. As research continues to evolve, the collective goal remains unwavering: to navigate the complexities of this pandemic with resilience, ensuring that the journey toward a safer tomorrow is informed by the lessons of today.
Vaccines that protect against severe illness, death and lingering long Covid symptoms from a Covid-19 infection are linked to small increases in neurological, blood, and heart-related conditions, according to the largest global vaccine safety study to date.
The study is likely to deepen the debate over the relative merits of getting vaccinated and whether the response was proportional.
Researchers stress that the risk of an adverse event from a Covid vaccine remains relatively low and that association does not prove causation.
However, among the 13.5 billion doses administered globally, a small proportion of people immunised developed complications, fuelling a debate over the trade-offs involved.
The rare events identified early in the pandemic included a higher risk of heart-related inflammation
Getty Images
The rare events identified early in the pandemic included a higher risk of heart-related inflammation from mRNA shots made by Pfizer Inc, BioNTech SE, and Moderna Inc, and an increased risk of a type of blood clot in the brain after immunisation with viral-vector vaccines such as the one developed by the University of Oxford and made by AstraZeneca Plc.
The viral-vector jabs were also tied to an increased risk of Guillain-Barre syndrome, a neurological disorder in which the immune system mistakenly attacks the peripheral nervous system.
The new research, by the Global Vaccine Data Network, dove further into the data. The full results are published in the journal Vaccine.
Researchers looked for 13 medical conditions that the group considered adverse events of special interest among 99 million vaccinated individuals in eight countries, aiming to identify higher-than-expected cases after a Covid shot.
Myocarditis, or inflammation of the heart muscle, was consistently identified following a first, second and third dose of mRNA vaccines, the study found.
The highest increase in the observed-to-expected ratio was seen after a second jab with the Moderna shot. A first and fourth dose of the same vaccine was also tied to an increase in pericarditis, or inflammation of the thin sac covering the heart.
Researchers found a statistically significant increase in cases of Guillain-Barre syndrome within 42 days of an initial Oxford-developed ChAdOx1 or Vaxzevria shot that wasnt observed with mRNA vaccines.
Based on the background incidence of the condition, 66 cases were expected but 190 events were observed. ChAdOx1 was linked to a threefold increase in cerebral venous sinus thrombosis, a type of blood clot in the brain, identified in 69 events, compared with an expected 21.
The small risk led to the vaccines withdrawal or restriction in Denmark and multiple other countries. Myocarditis was also linked to a third dose of ChAdOx1 in some, but not all, populations studied. Possible safety signals for transverse myelitis spinal cord inflammation after viral-vector vaccines was identified in the study.
Widespread immunity through vaccination allowed the UK to lift lockdown measures
So was acute disseminated encephalomyelitis inflammation and swelling in the brain and spinal cord after both viral-vector and mRNA vaccines.
Seven cases of acute disseminated encephalomyelitis after vaccination with the Pfizer-BioNTech vaccine were observed, versus an expectation of two.
The adverse events of special interest were selected based on pre-established associations with immunisation, what was already known about immune-related conditions and preclinical research. The study didnt monitor for postural orthostatic tachycardia syndrome, or POTS, that some research has linked with Covid vaccines.
This the largest study to date looking at the risks associated with Covid vaccination. The size of the study sample is pause for thought but the number of people injured is relatively small when compared to the people immunised without incident.
It's also important to understand the bigger picture here. Covid was a moving target and so were the interventions taken to stop it.
Furthermore, widespread immunity offered through vaccination allowed the UK to lift lockdown measures, revive the economy and restore a sense of normality to back to people's lives.
And numerous studies suggest vaccination saved lives. The largest study of its kind ever carried out in the UK has found that 7,180 of the 40,393 hospitalisations and deaths from COVID-19 could have been avoided had the population been fully vaccinated.
Still, those left injured by vaccination are demanding answers and dissent should not be silenced - a point powerfully articulated by a man who recently confronted Rishi Sunak over Covid vaccine injuries on GB News.
PORTLAND, Ore. As the Centers for Disease Control and Prevention (CDC) eyes easing its five-day isolation policy for those who test positive for COVID-19, the Oregon Health Authority (OHA) had already adopted that practice in May 2023.
The OHA's policy is that someone with COVID-19 doesnt need to stay home for five days.
"Were seeing a lot less severe disease than we had early on in the pandemic, given the amount of people who are vaccinated already, have recovered from COVID-19 or both and had some level of immunity," said Dr. Dean Sidelinger, Oregon's state epidemiologist. "So that is what contributed to our decision back in May."
OHA recommends people now look at symptoms to determine when it is time to stop isolating. With the new approach, the agency said people don't need to stay home if they are fever-free for 24 hours without medication and have mild or improving symptoms.
"COVID can be unpredictable, but so far, we are seeing a slow steady decline," Sidelinger said. "Our vaccines work to protect people from the variants that have emerged over the past couple of years. COVID is coming down, influenza is coming down and RSV is coming down."
As of February, emergency room visits, hospitalizations and deaths from COVID-19 are down, according to the latest CDC data.
RELATED: Nearly 10,000 died from COVID-19 in December, fueled by holiday gatherings and new variant, WHO says
To keep this immunity up, OHA said it is important for people to stay up to date on vaccinations, especially when it comes to kids in school.
On Saturday, Multnomah County held a free catch-up clinic for children still needing their immunizations at David Douglas High School. If they dont meet this requirement by Feb. 21, they will be turned away from all schools or daycares.
"We want to make sure that our communities are protected," said Richard Bruno, the Multnomah County Public Health Officer. "We want to have very low-barrier access to vaccines that are needed. We dont check for insurance and have a great supply of vaccines available for anybody who needs it."
For parents who missed Saturday's clinic, they still have another chance to get their children up to date on vaccines. On Feb. 21, Multnomah County will hold its final immunization clinic with CareOregon Boys & Girls Club in Rockwood from 8:30 a.m. to noon.
Meanwhile, the CDC is still recommending that people who test positive for COVID-19 stay home for at least five days and isolate themselves from others in their home. People should also wear a high-quality mask if they have to be around others in their home during the isolation period, according to current guidelines.
State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada
Zip Code
Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe
Only 50% of nursing home residents in Maine have received the latest COVID vaccine, according to data from the U.S. CDC. That's down from 90% just over a year ago. A new analysis by the Kaiser Family Foundation says one reason for declining vaccination rates is the absence of federal initiatives such as clinics.
Angela Westhoff, CEO of the Maine Health Care Association, says another factor is vaccine fatigue.
"As we have seen cases of COVID come down and the mortality rate has dropped dramatically from where we were at the height of the pandemic, sometimes that equates to people not being interested or as interested in getting another vaccine or a booster to up to date on their shots," she says.
Maine 's 50% nursing home vaccination rate is lower than the 76% in Vermont, but higher than the U.S. average of 40%.
Westhoff says the Association is currently working with Maine's Long Term Care Ombudsman on a campaign to boost vaccinations at long term care facilities.
A walk-in flu and COVID-19 vaccination clinic will be held from noon to 2 p.m. Wednesday, Feb. 21.
The clinic will be at 201 Wheatsworth Road, Hamburg. No appointment needed.
The flu vaccine costs $25 and the high-dose flu vaccine costs $65. They are free for those insured with Medicare Part B. No out-of-pocket fee for those insured with any Blue Cross Blue Shield plan. No other type of insurance accepted. Please bring insurance card.
The updated COVID-19 vaccine is available at no cost.
The clinic is sponsored by the Sussex County Office of Public Health Nursing.
For information, call 973-579-0570 ext. 1275 or go online to scphn@sussex.nj.us
In the largest global vaccine safety study to date, vaccines guarding against severe COVID-19 outcomes were linked to rare neurological, blood, and heart-related conditions. The Global Vaccine Data Networks research, encompassing 99 million vaccinated individuals across eight countries, revealed small increases in adverse events, including heart-related inflammation from mRNA shots and heightened risks with viral-vector vaccines. The study emphasises the need for balance in weighing the benefits versus harms of the over 13.5 billion COVID vaccine doses administered worldwide over the past three years.
Sign up for your early morning brew of the BizNews Insider to keep you up to speed with the content that matters. The newsletter will land in your inbox at 5:30am weekdays. Registerhere.
ByJason Gale
Vaccines that protect against severe illness, death and lingeringlong Covidsymptoms from a coronavirus infection were linked to small increases in neurological, blood, and heart-related conditions in the largest globalvaccine safetystudy to date.
The rare events identified early in the pandemic included a higher risk of heart-relatedinflammationfrommRNAshots made by Pfizer Inc., BioNTech SE, and Moderna Inc., and an increased risk of a type of blood clot in the brain after immunization withviral-vector vaccinessuch as the one developed by the University of Oxford and made by AstraZeneca Plc.
The viral-vector jabs were also tied to an increased risk ofGuillain-Barre syndrome, a neurological disorder in which the immune system mistakenly attacks the peripheral nervous system.
More than 13.5 billion doses of Covid vaccines have been administered globally over the past three years,savingover 1 million lives in Europe alone. Still, a small proportion of people immunized were injured by the shots, stoking debate about their benefits versus harms.
The new research, by the Global Vaccine Data Network, was published in the journal Vaccine last week, with the data made available via interactivedashboardsto show methodology and specific findings.
The research looked for 13 medical conditions that the group considered adverse events of special interest among 99 million vaccinated individuals in eight countries, aiming to identify higher-than-expected cases after a Covid shot. The use of aggregated data increased the possibility of identifying rare safety signals that might have been missed when looking only at smaller populations.
Myocarditis, or inflammation of the heart muscle, was consistently identified following a first, second and third dose of mRNA vaccines, the study found. The highest increase in the observed-to-expected ratio was seen after a second jab with the Moderna shot. A first and fourth dose of the same vaccine was also tied to an increase in pericarditis, or inflammation of the thin sac covering the heart.
Researchers found a statistically significant increase in cases ofGuillain-Barre syndromewithin 42 days of an initial Oxford-developed ChAdOx1 or Vaxzevria shot that wasnt observed with mRNA vaccines. Based on the background incidence of the condition, 66 cases were expected but 190 events were observed.
ChAdOx1 was linked to a threefold increase in cerebral venous sinus thrombosis, a type of blood clot in the brain, identified in 69 events, compared with an expected 21. The small risk led to the vaccines withdrawal or restriction inDenmarkand multiple other countries. Myocarditis was also linked to a third dose of ChAdOx1 in some, but not all, populations studied.
Possible safety signals fortransverse myelitis spinal cord inflammation after viral-vector vaccines was identified in the study. So wasacute disseminated encephalomyelitis inflammation and swelling in the brain and spinal cord after both viral-vector and mRNA vaccines.
Seven cases of acute disseminated encephalomyelitis after vaccination with the Pfizer-BioNTech vaccine were observed, versus an expectation of two.
The adverse events of special interest were selected based on pre-established associations with immunization, what was already known about immune-related conditions and pre-clinical research. The study didnt monitor forpostural orthostatic tachycardia syndrome, or POTS, that some research haslinkedwith Covid vaccines.
Exercise intolerance, excessive fatigue, numbness and brain fog were among common symptoms identified in more than 240 adults experiencing chronicpost-vaccinationsyndrome in a separatestudyconducted by the Yale School of Medicine. The cause of the syndrome isnt yet known, and it has no diagnostic tests or proven remedies.
The Yale research aims to understand the condition to relieve the suffering of those affected and improve the safety of vaccines, said Harlan Krumholz, a principal investigator of the study, and director of the Yale New Haven Hospital Center for Outcomes Research and Evaluation.
Both things can be true, Krumholz said in an interview. They can save millions of lives, and there can be a small number of people whove been adversely affected.
Read also:
2024Bloomberg L.P.
Visited 85 times, 85 visit(s) today
In a collaboration with @WhatToExpect, the Centers for Disease Control and Prevention (CDC) has provided updated COVID-19 vaccine guidelines for pregnant women and children. This move underscores an ongoing commitment to protect the most vulnerable from the severe impacts of the virus. These guidelines emphasize the importance of receiving the COVID-19 vaccine during pregnancy to protect both the mother and baby from severe illness that may require hospitalization.
The CDCs updated recommendations on Instagram provide comprehensive information about the safety and efficacy of the COVID-19 vaccine for pregnant women and children. The organization underscores the importance of vaccination in these groups as a vital measure to protect them from the virus. Visit the CDCs Instagram page to learn more about their informative and practical advice related to COVID-19 vaccinations. (Link)
According to the CDC, receiving the COVID-19 vaccine during pregnancy can help safeguard both the mother and baby from severe illness that may require hospitalization. In addition to this, the vaccine can also reduce the risk of preterm birth and other adverse pregnancy outcomes associated with COVID-19.
Although pregnant people are at a higher risk for severe illness from COVID-19 compared to non-pregnant people, vaccination rates among this group remain low. Thus, it is essential to spread awareness about the importance and safety of COVID-19 vaccination during pregnancy. The CDC continues to recommend that all pregnant people or people who are thinking about becoming pregnant get vaccinated against COVID-19.
Recent research from the National Institute of Allergy and Infectious Diseases (NIAID) highlights another significant benefit of COVID-19 vaccination during pregnancy: it can provide infants with strong protection against symptomatic COVID-19 infection for at least six months after birth.
The study found that infants born to mothers who received both doses of an mRNA COVID-19 vaccine as well as a COVID-19 booster had higher levels of antibodies at birth and greater protection from COVID-19 infection during their first six months. This research is particularly crucial as no COVID-19 vaccines are currently available for infants under six months old. The full details of this study can be found on the NIH website. (Link)
As the world continues to navigate the COVID-19 pandemic, ensuring the safety and health of vulnerable groups like pregnant women and children remains a top priority. The latest guidelines and research from the CDC and NIAID offer valuable insights into how we can protect these groups and underline the importance of vaccination. By getting vaccinated, pregnant women not only protect themselves but also significantly enhance the health and safety of their newborns.
Lets align with science, trust our health experts, and ensure a healthier future for ourselves and the generations to come by getting vaccinated against COVID-19. Remember, every shot counts in our fight against this global pandemic.
